Andrew Craig Miller - Apr 18, 2023 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role
Chief Operating Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Stock symbol
KRTX
Transactions as of
Apr 18, 2023
Transactions value $
-$8,652,550
Form type
4
Date filed
4/20/2023, 06:17 PM
Previous filing
Feb 13, 2023
Next filing
Feb 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $276K +30K +97.09% $9.20* 60.9K Apr 18, 2023 Direct
transaction KRTX Common Stock Sale -$6M -30K -49.26% $200.16 30.9K Apr 18, 2023 Direct F1, F2
transaction KRTX Common Stock Options Exercise $78.2K +8.5K +27.51% $9.20* 39.4K Apr 20, 2023 Direct
transaction KRTX Common Stock Sale -$3M -15K -38.07% $200.13 24.4K Apr 20, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -30K -11.09% $0.00 240K Apr 18, 2023 Common Stock 30K $9.20 Direct F3
transaction KRTX Option (right to buy) Options Exercise $0 -8.5K -3.53% $0.00 232K Apr 20, 2023 Common Stock 8.5K $9.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 16, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.04 to $200.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 This option vested and became exercisable in thirty equal monthly installments beginning on April 21, 2019.